Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia ...

Quest Diagnostics Inc resolved allegations that its prenatal DNA tests infringed a patent owned by biotech company Ravgen Inc on Friday shortly before a trial in Los Angeles federal court was set ...

Quest Diagnostics Inc. said Monday the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease is now available for consumer purchase.

Quest Diagnostics DGX recently launched a novel prostate cancer biomarker test through its subspecialty pathology business unit, AmeriPath. The laboratory test is developed in collaboration with ...

Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript April 22, 2025 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.21, expectations were $2.15.

The test, which you order online, will be available from most of Quest's approximately 2,100 diagnostic centers in the country and will include (if desired) a separate telephone consultation with ...

Medicare covers many tests at Quest Diagnostics — as long as your doctor and Quest location participate in Medicare and the test you're getting is medically necessary. Learn more.

CLEVELAND, Ohio — University Hospitals has sold some of its outpatient laboratory locations to New Jersey-based Quest Diagnostics for an undisclosed amount, Quest announced. The sale, first ...

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's protein which can appear years before dementia symptoms arise.

Barring New York, physicians in the United States may order the test with immediate effect. Industry Prospects. The global prostate cancer therapeutics market was valued at $12.12 billion in 2022 ...